Periodontal disease and the oral-systemic connection: "Is it all the RAGE?"

Quintessence International

Volumn 41, Issue 3, 2010, Pages 229-237

  Katz, Joseph ^a   Wallet, Shannon ^a   Cha, Seunghee ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

Cardiovascular disease; Diabetes; Periodontal disease; RAGE

Indexed keywords

ADVANCED GLYCOSYLATION END PRODUCT RECEPTOR; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN RECEPTOR; INTEGRIN; LIGAND;

AGING; ALZHEIMER DISEASE; ANIMAL; ARTICLE; CARDIOVASCULAR DISEASE; CHEMISTRY; CHRONIC DISEASE; DIABETES MELLITUS; FEMALE; HUMAN; METABOLISM; PERIODONTAL DISEASE; PHYSIOLOGY; PREGNANCY; PREMATURITY; SIGNAL TRANSDUCTION; SMOKING; SQUAMOUS CELL CARCINOMA; TONGUE TUMOR;

AGING; ALZHEIMER DISEASE; ANIMALS; CARCINOMA, SQUAMOUS CELL; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; DIABETES COMPLICATIONS; DIABETES MELLITUS; FEMALE; HMGB1 PROTEIN; HUMANS; INTEGRINS; LIGANDS; PERIODONTAL DISEASES; PREGNANCY; PREMATURE BIRTH; RECEPTORS, IMMUNOLOGIC; SIGNAL TRANSDUCTION; SMOKING; TONGUE NEOPLASMS;

EID: 77953056295     PISSN: 00336572     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (72)

1. Paquette DW, Madianos P, Offenbacher S, Beck JD, Williams RC. The concept of "risk"and the emerging discipline of periodontal medicine. J Contemp Dent Pract 1999; 1: 1-18.
2. Meng H, Xu L, Li Q, Han J, Zhao Y. Determinants of host susceptibility in aggressive periodontitis. Periodontol 2000 2007; 43: 133-159.
3. Lalla E, Lamster IB, Feit M, et al. Blockade of RAGE suppresses periodontitis-associated bone loss in diabetic mice. J Clin Invest 2000; 105: 1117-1124.
4. Yan SF, Ramasamy R, Schmidt AM. The receptor for advanced glycation endproducts (RAGE) and cardiovascular disease. Expert Rev Mol Med 2009; 11:e9.
5. Gotsman I, Lotan C, Soskolne WA, et al. Periodontal destruction is associated with coronary artery disease and periodontal infection with acute coronary syndrome. J Periodontol 2007; 78: 849-858.
6. Tabrizi F, Buhlin K, Gustafsson A, Klinge B. Oral health of monozygotic twins with and without coronary heart disease: A pilot study. J Clin Periodontol 2007; 34: 220-225.
7. D'Aiuto F, Ready D, Tonetti MS. Periodontal disease and C-reactive protein-associated cardiovascular risk. J Periodontal Res 2004; 39: 236-241.
8. DeStephano F, Anda RF, Kahn HS, et al. Dental disease and risk of coronary heart disease and mortality. BMJ 1993; 306: 688-691.
9. Elter JR, Champagne CM, Offenbacher S, Beck JD. Relationship of periodontal disease and tooth loss to prevalence of coronary heart disease. J Periodontol 2004; 75: 782-790.
10. Briggs JE, McKeown PP, Crawford VL, et al. Angiographically confirmed coronary heart disease and periodontal disease in middle-aged males. J Periodontol 2006; 77: 95-102.
11. Holmlund A, Holm G, Lind L. Severity of periodontal disease and number of remaining teeth are related to the prevalence of myocardial infarction and hypertension in a study based on 4,254 subjects. J Periodontol 2006; 77: 1173-1178.
12. Desvarieux M, Schwahn C, Volzke H, et al. Gender differences in the relationship between periodontal disease, tooth loss, and atherosclerosis.Stroke 2004; 35: 2029-2035.
13. Taylor BA, Tofler GH, Carey HM, et al. Full-mouth tooth extraction lowers systemic inflammatory and thrombotic markers of cardiovascular risk. J Dent Res 2006; 85: 74-78.
14. Diabetes and periodontal diseases. Committee on Research, Science, and Therapy. American Academy of Periodontology. J Periodontol 2000; 71: 664-678.
15. Khader YS, Dauod AS, El-Qaderi SS, Alkafajei A, Batayha WQ. Periodontal status of diabetics compared with nondiabetics: A meta-analysis. J Diabetes Complications 2006; 20: 59-68.
16. Loe H. Periodontal disease. The sixth complication of diabetes mellitus.Diabetes Care 1993; 16: 329-334.
17. Grossi SG, Genco RJ. Periodontal disease and diabetes mellitus: A two-way relationship. Ann Periodontol 1998; 3: 51-61.
18. Taylor GW, Burt BA, Becker MP, et al. Severe periodontitis and risk for poor glycemic control in patients with non-insulin-dependent diabetes mellitus. J Periodontol 1996; 67: 1085-1093.
19. King GL. The role of inflammatory cytokines in diabetes and its complications. J Periodontol 2008; 79: 1527-1534.
20. Nishimura F, Murayama Y. Periodontal inflammation and insulin resistance-Lessons from obesity. J Dent Res 2001; 80: 1690-1694.
21. Kamer AR, Dasanayake AP, Craig RG, Glodzik-Sobanska L, Bry M, de Leon MJ. Alzheimer's disease and peripheral infections:The possible contribution from periodontal infections, model and hypothesis. J Alzheimers Dis 2008; 13: 437-449.
22. Meyer MS, Joshipura K, Giovannucci E, Michaud DS. A review of the relationship between tooth loss, periodontal disease, and cancer. Cancer Causes Control 2008; 19: 895-907.
23. Migliorati CA. Periodontal diseases and cancer. Lancet Oncol 2008; 9: 510-512.
24. Michaud DS, Liu Y, Meyer M, Giovannucci E, Joshipura K. Periodontal disease, tooth loss, and cancer risk in male health professionals: A prospective cohort study. Lancet Oncol 2008; 9: 550-558.
25. Michaud D, Joshipura K, Giovannucci E, Fuchs C. A prospective study of periodontal disease and pancreatic cancer in US male health professionals. J Natl Cancer Inst 2007; 99: 171-175.
26. Tezal M, Sullivan M, Reid M, et al. Chronic periodontitis and the risk of tongue cancer. Arch Otolaryngol Head Neck Surg 2007; 133: 450-454.
27. Hujoel P, Drangsholt M, Spiekerman C, Weiss N. An exploration of the periodontitis-cancer association. Ann Epidemiol 2003; 13: 312-316.
28. Dasanayake AP, Boyd D, Madianos PN, et al. The association between Porphyromonas gingivalis-specific maternal serum IgG and low birth weight. J Periodontol 2001; 72: 1491-1497.
29. Offenbacher S, Boggess KA, Murtha AP, et al. Progressive periodontal disease and risk of very preterm delivery. Obstet Gynecol 2006; 107: 29-36.
30. Yalcin F, Basegmez C, Isik G, et al. The effects of periodontal therapy on intracrevicular prostaglandin E2 concentrations and clinical parameters in pregnancy. J Periodontol 2002; 73: 173-177.
31. Jeffcoat MK, Hauth JC, Geurs NC, et al. Periodontal disease and preterm birth: Results of a pilot intervention study. J Periodontol 2003; 74: 1214-1218.
32. Stern D, Yan SD, Yan SF, Schmidt AM. Receptor for advanced glycation endproducts: A multiligand receptor magnifying cell stress in diverse pathologic settings. Adv Drug Deliv Rev 2002; 54: 1615-1625.
33. Hofmann MA, Drury S, Fu C, et al. RAGE mediates a novel proinflammatory axis: A central cell surface receptor for S100/calgranulin polypeptides. Cell 1999; 97: 889-01.
34. Clynes R, Moser B, Yan SF, Ramasamy R, Herold K, Schmidt AM. Receptor for AGE (RAGE):Weaving tangled webs within the inflammatory response. Curr Mol Med 2007; 7: 743-751.
35. Bierhaus PM, Humpert M, Morcos T, et al. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med 2005; 83: 876-886.
36. Falcone C, Emanuele D, D'Angelo A, et al. Plasma levels of soluble receptor for advanced glycation endproducts and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol 2005; 25: 1032-1037.
37. Geroldi D, Falcone C, Emanuele D. Soluble receptor for advanced glycation end products: From disease marker to potential therapeutic target. Curr Med Chem 2006; 13: 1971-1978.
38. Pillerits R, Bokarewa M, Dahlberg L, Tarkowski A. Decreased levels of soluble receptor for advanced glycation endproducts in patients with rheumatoid arthritis indicating insufficient inflammatory control. Arthritis Res Ther 2005; 7:R817-R824.
39. Hofmann MA, Drury S, Hudson BI, et al. RAGE and arthritis: The G82S polymorphism amplifies the inflammatory response. Genes Immun 2002; 3: 123-135.
40. Katz J, Caudle RM, Bhattacharyya I, Stewart CM, Cohen DM. Receptor for advanced glycation end product (RAGE) upregulation in human gingival fibroblasts incubated with nornicotine. J Periodontol 2005; 76: 1171-1174.
41. Katz J, Yoon TY, Mao S, Lamont RJ, Caudle RM. Expression of the receptor of advanced glycation end products in the gingival tissue of smokers with generalized periodontal disease and after nornicotine induction in primary gingival epithelial cells. J Periodontol 2007; 78: 736-741.
42. Bidwell JP, Yang J, Robling AG. Is HMGB1 an osteocyte alarmin? J Cell Biochem 2008; 103: 1671-1680.
43. Franke S, Siggelkow H, Wolf G, Hein G. Advanced glycation endproducts influence the mRNA expression of RAGE, RANKL and various osteoblastic genes in human osteoblasts. Arch Phys Biol 2007; 113: 154-161.
44. Hein GE. Glycation endproducts in osteoporosis-Is there a pathophysiologic importance? Clin Chim Acta 2006; 371: 32-26.
45. Seymour GJ, Ford PJ, Cullinan MP, Leishman S, Yamazaki K. Relationship between periodontal infections and systemic disease. Clin Microbiol Infect 2007; 13: 3-10.
46. Katz J, Bhattacharyya I, Farkhondeh-Kish F, Perez FM, Caudle RM, Heft MW. Expression of the receptor of advanced gycation end products in gingival tissues of type 2 diatetes patients with chronic periodontal disease: A study untilizing immunohistochemistry and RT-PCR. J Clin Periodonal 2005; 32: 40-44.
47. Katz J, Yoon TY, Mao S, Lamont RJ, Caudle RM. Expression of the receptor of advanced glycation end products in the gingival tissue of smokers with generalized periodontal disease and after nornicotine induction in primary gingival epithelial cells. J Periodontol 2007; 78: 736-741.
48. Katz J, Caudle RM, Bhattacharyya I, Stewart CM, Cohen DM. Receptor for advaced glycation end product (RAGE) upregulation in human gingival fibroblasts incubated with nornicotine. J Periodontol 2005; 76: 1171-1174.
49. Cipollone F, Iezzi A, Fazia M, et al. The receptor RAGE as a progression factor amplifying arachidonatedependent inflammatory and proteolytic response in human atherosclerotic plaques: Role of glycemic control. Circulation 2003; 108: 1070-1077.
50. Burke AP, Kolodgie FD, Zieske A, et al. Morphologic findings of coronary atherosclerotic plaques in diabetics:A postmortem study. Arterioscler Thromb Vasc Biol 2004; 24: 1266-1271.
51. Koyama H, Yamamoto H, Nishizawa Y. RAGE and soluble RAGE: Potential therapeutic targets for cardiovascular diseases. Mol Med 2007; 13: 625-635.
52. Bucciarelli LG, Wendt T, Qu W, et al. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 2002; 106: 2827-2835.
53. Brownlee M. Advanced protein glycosylation in diabetes and aging. Annu Rev Med 1995; 46: 223-234.
54. Bucciarelli LG, Wendt T, Rong L, et al. RAGE is a multiligand receptor of the immunoglobulin superfamily:Implications for homeostasis and chronic disease. Cell Mol Life Sci 2002; 59: 1117-1128.
55. Tanaka H, Yonekura S, Yamagishi H, Fujimori Y, Yamamoto H, Yamamoto H. The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells. J Biol Chem 2000; 275: 25781-25790.
56. Yamamoto Y, Kato I, Doi T, et al. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest 2001; 108: 261-268.
57. Inagi R, Yamamoto Y, Nangaku M, et al. A severe diabetic nephropathy model with early development of nodule-like lesions induced by megsin overexpression in RAGE/iNOS transgenic mice. Diabetes 2006; 55: 356-366.
58. Schmidt AM, Yan SD, Wautier JL, Stern D. Activation of receptor for advanced glycation end products: A mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 1999; 84: 489-497.
59. Takeuchi M, Yamagishi S. Possible involvement of advanced glycation end-products (AGEs) in the pathogenesis of Alzheimer's disease. Curr Pharm Des 2008; 14: 973-978.
60. Chen X, Walker DG, Schmidt AM, Arancio O, Lue LF, Yan SD. RAGE: A potential target for Abeta-mediated cellular perturbation in Alzheimer's disease. Curr Mol Med 2007; 7: 735-742.
61. Lue LF, Yan SD, Stern DM, Walker DG. Preventing activation of receptor for advanced glycation end products in Alzheimer's disease. Curr Drug Targets CNS Neurol Disord 2005; 4: 249-266.
62. Bierhaus A, Stern DM, Nawroth PP. RAGE in inflammation:A new therapeutic target? Curr Opin Investig Drugs 2006; 7: 985-991.
63. Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: Sparking the development of diabetic vascular injury. Circulation 2006; 114: 597-605.
64. Taguchi DC, Blood G, del Toro A, et al. Blockade of RAGE-amphoterin signaling suppresses tumour growth and metastases. Nature 2000; 405: 354-360.
65. Logsdon CD, Fuentes MK, Huang EH, Arumugam T. RAGE and RAGE ligands in cancer. Curr Mol Med 2007; 7: 777-789.
66. Abe R, Yamagishi S. AGE-RAGE system and carcinogenesis. Curr Pharm Des 2008; 14: 940-945.
67. Buhimschi IA, Zhao G, Pettker CM, et al. The receptor for advanced glycation end products (RAGE) system in women with intraamniotic infection and inflammation. Am J Obstet Gynecol 2007; 196: 181.e1-13.
68. Romero R, Espinoza J, Hassan S, et al. Soluble receptor for advanced glycation end products (sRAGE) and endogenous secretory RAGE (esRAGE) in amniotic fluid: Modulation by infection and inflammation. J Perinat Med 2008; 36: 388-398.
69. Hájek Z, Germanová A, Kouck M, et al. Detection of feto-maternal infection/inflammation by the soluble receptor for advanced glycation end products (sRAGE): Results of a pilot study. J Perinat Med 2008; 36: 399-404.
70. Cai W, He JC, Zhu L, et al. Reduced oxidant stress and extended lifespan in mice exposed to a low glycotoxin diet. Am J Pathol 2007; 170: 1893-1902.
71. Vlassara H, Uribarri J, Cai W, Striker G. Advanced glycation end products homeostasis. Ann NY Acad Sci 2008; 1126: 46-52.
72. Dickerson TJ, Janda KD. A previously undescribed chemical link between smoking and metabolic disease. Proc Natl Acad Sci USA 2002; 99: 15084-15088.